Philippe Laffont’s Moderna MRNA Stock Holding History

Philippe Laffont’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$5.9M	–	70
2025 Q4	$5.9M	Buy	+200,000	New	+$5.43M	0.01%	50
2025 Q1	–	Sell	-191,074	Closed	-$7.94M	–	80
2024 Q4	$7.94M	Buy	+191,074	New	+$9.13M	0.03%	62
2024 Q1	–	Sell	-3,273,052	Closed	-$326M	–	110
2023 Q4	$326M	Sell	3,273,052 -1,636,526	-33%	-$138M	1.37%	20
2023 Q3	$507M	Sell	4,909,578 -1,636,526	-25%	-$183M	2.57%	12
2023 Q2	$795M	Hold	6,546,104	–	–	3.9%	8
2023 Q1	$1.01B	Buy	6,546,104 +152,539	+2%	+$25.2M	6.68%	4
2022 Q4	$1.15B	Buy	6,393,565 +687,061	+12%	+$112M	12.88%	1
2022 Q3	$675M	Buy	5,706,504 +173	+0%	+$26.3K	7.83%	2
2022 Q2	$815M	Sell	5,706,331 -1,221,816	-18%	-$175M	9.86%	2
2022 Q1	$1.19B	Buy	6,928,147 +2,641,144	+62%	+$445M	8.73%	3
2021 Q4	$1.09B	Sell	4,287,003 -1,761,923	-29%	-$515M	4.83%	3
2021 Q3	$2.33B	Sell	6,048,926 -91,978	-1%	-$33.9M	9.47%	1
2021 Q2	$1.44B	Buy	6,140,904 +4,883,219	+388%	+$873M	5.59%	3
2021 Q1	$165M	Buy	+1,257,685	New	+$182M	0.9%	30

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Philippe Laffont's MRNA Position: Q1 2026 in Review

Philippe Laffont sold out of Moderna (MRNA) in Q1 2026, closing a stake of 200,000 shares — an estimated $5.9M sold.

Philippe Laffont first reported a position in MRNA in Q1 2021 and held it in 14 quarters. The position peaked at $2.33B in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Philippe Laffont reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Philippe Laffont sold 200,000 Moderna shares in Q1 2026, an estimated $5.9M.
Philippe Laffont first reported a position in Moderna in Q1 2021 and held it in 14 quarters.
Philippe Laffont's Moderna position peaked at $2.33B in Q3 2021.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Coatue Management's 13F filing for Q1 2026, filed 15 May 2026.